Morgan Stanley analyst Terence Flynn raised the firm’s price target on Gilead (GILD) to $147 from $143 and keeps an Overweight rating on the shares. Gilead’s FY25 guidance for its new Yeztugo HIV PReP launch of $150M implies Q4 sales could come in below the firm’s and Visible Alpha consensus forecasts, but the firm believes this is simply a function of building payer access and takes “comfort” from the robust Descovy PReP trends, the analyst tells investors in a post-Q3 note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead price target raised to $105 from $100 at RBC Capital
- Hookipa Pharma completes sale of HBV, HIV assets to Gilead
- Gilead price target raised to $150 from $145 at JPMorgan
- Gilead Sciences: Strong Q3 2025 Performance and Growth Potential Justify Buy Rating
- Gilead price target raised to $145 from $140 at Wells Fargo